Liposomes and their therapeutic: State of art applications;Lipossomas e suas aplicações terapêuticas: Estado da arte

Revista Brasileira de Ciencias Farmaceuticas/Brazilian Journal of Pharmaceutical Sciences

Volumn 43, Issue 2, 2007, Pages 167-179

  Batista, Cinthia Meireles ^a   De Carvalho, Cícero Moraes Barros ^a   Magalhães, Nereide Stela Santos ^a  

^a FEDERAL UNIVERSITY OF PERNAMBUCO   (Brazil)

Author keywords

Liposomes; Phospholipids; Stability; Therapeutic applications

Indexed keywords

DIAGNOSTIC AGENT; DRUG CARRIER; LIPOSOME; PHOSPHOLIPID DERIVATIVE; STEALTH; UNCLASSIFIED DRUG;

DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STABILITY; DRUG TARGETING; HYDROPHILICITY; PHAGOCYTOSIS; PHYSICAL CHEMISTRY; REVIEW; TRANSPORT VESICLE;

EID: 34548261850     PISSN: 15169332     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-93322007000200003     Document Type: Review

References (66)

1. AMSELEM, S., GABIZON, A., BARENHOLZ, Y. A large scale method for the preparation of sterile and nonpyrogenic liposomal formulations of defined size distributions for clinical use. In: GREGORIADIS, G. (Ed.). 2. ed. Liposome technology. Boca Raton: CRC Press, 1993. v. 1, p. 459, p. 501-525.
2. ANABOUSI, S., BAKOWSKY, U., SCHNEIDER, M., HUWER, H., LEHR, C.-M., CHRARDT, C. In vitro assessement of transferrin-conjugated liposomes as drug delivery systems for inhalation therapy of lung cancer. Eur. J. Pharm. Sci., v. 29, p.367-374, 2006.
3. ANDRADE, C. A. S.; CORREIA, M. T. S.; COELHO, L. C. B. B.; NASCIMENTO, S. C.; SANTOS-MAGALHÃES, N. S. Antitumor activity of Cratylia mollis lectin encapsulated into liposomes. Int. J. Pharm., Amsterdam, v. 278, p.435-445, 2004.
4. ANDRESEN, T. L.; JENSEN, S. S.; JORGENSEN, K. Advanced strategies in liposomal cancer therapy: Problems and prospects of active and tumor specific drug release. Prog. Lipid Res., Oxford, v. 44, p.68-97, 2005.
5. BADIEE, A.; JAAFARI, M.R.; KHAMESIPOUR, A. Leishmania major: Immune response in BALB/c mice immunized with stree-inducible protein 1 encapsulated in liposomes. Exp. Parasitol., v. 115, p. 127-134, 2007.
6. BANERJEE, R. Liposomes: aplications in medicine. J. Biomat. Applied, London, v. 16, p. 3-21, 2001.
7. BEN-YEHUDA, A.; JOSEPH, A.; BARENHOLZ, Y.; ZEIRA, E.; EVEN-CHEN, S.; LOURIA-HAYON, I.; BABAI, I.; ZAKAY-RONES, Z.; GREENBAUM, E.; GALPRIN, I.; GLÜCK, R.; ZURBRIGGEN, R.; KEDAR, E. Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. Vaccine, Kidlinton, v. 21, p. 3169-3178, 2003.
8. CACELA, C.; HINCHA, D. K. Low amounts of sucrose are sufficient to depress the phase transition temperature of dry phosphatidylcholine, but not for lyoprotection of liposomes. Biophys. J., Bethesda, v. 90, p.2831-2842, 2006.
9. CARNEIRO, A.L.; SANTANA, M. H. A. Production of liposomes in a multitubular system useful for scaling-up of processes. In: GALEMBEK, F. (Ed.). Progress in Colloid & Polymer Science, Surface and Colloid Science. New York: Springer, 2004. v. 128, p. 273-276.
10. CARVALHO Jr, A. D.; MOTA, L.G.; NUNAN, E. A.; WAINSTEIN, A. J. A.; WAINSTEIN, A.P.D.L.; LEAL, A. S.; CARDOSO, V. N.; OLIVEIRA, M. C. Tissue distribution evaluation of stealth pH-sensitive liposomal cisplatin versus free cisplatin in Ehrlich tumor bearing mice. Life Sci., v. 80, p. 659-664, 2007.
11. CHONN, A.; CULLIS, P. R. Recent advances in liposomes technologies and their applications for systemic gene delivery. Adv. Drug Del. Rev., Amsterdam, v. 30, p. 73-83, 1998.
12. CHOU, H.; WANG, K.; CHEN, C.; WEI, L.; LAI, C.; HSIEH, C.; YANG, Y.; TWU, N.; CHANG, T.; YEN, M. Pegylated liposomal doxorubicin (Lipo-Dox®) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long-term follow-up. Gynecol. Oncol., New York, v. 101, p.423-428, 2006.
13. DASS, C. R.; CHOONG, P. F. M. Carrier-mediated delivery of peptidic drugs for cancer therapy. Peptides, New York, v. 27, p. 3020-3028, 2006.
14. DERYCKE, A. S. L.; WITTE, P. A. M. Liposome for photodynamic therapy. Adv. Drug Del. Rev., Amsterdam, v. 56, p. 17-30, 2004.
15. EDWARDS, K. A.; BAEUMNER, A. J. Liposomes in analyses. Talanta, London, v. 68, n.5, p.1432-1441, 2006.
16. EL-ANEED, A. An overview of current delivery systems in cancer gene therapy. J. Controlled Release, Amsterdam, v. 94, p. 1-14, 2004.
17. FREUND, O.; AMÉDEE, J.; ROUX, D.; LAVERSANNE, R. In vitro and in vivo stability of new multilamellar vesicles. Life Sci., Elmsford, v. 67, p. 411-419, 2000.
18. FRÉZARD, F. Liposomes: from biophysics to the design of peptide vaccines. Braz. J. Med. Biol. Res., Ribeirão Preto, v. 32, p. 181-189, 1999.
19. FRÉZARD, F.; SCHETTINI, D. A.; ROCHA, O. G. F.; DEMICHELI, C. Lipossomas: propriedades físico-químicas e farmacológicas, aplicações na quimioterapia à base de antimônio. Quim. Nova, São Paulo, v. 28, p.511-518, 2005.
20. HATTORI, Y.; KAWAKAMI, S.; SUZUKI, S.; YAMASHITA F.; HASHIDA, M. Enhancement of immune responses by DNA vaccination through targeted gene delivery using mannosylated cationic liposome formulations following intravenous administration in mice. Biochem. Biophys. Res. Comm., Orlando, v. 317, p. 992-999, 2004.
21. KANEDA, Y. Virosomes: evolution of the liposome as a targeted drug delivery system. Adv. Drug Del. Rev., Amsterdam, v. 43, p. 197-205, 2000.
22. KERSTEN, G. F. A.; CROMMELIN, D. J. A. Liposomes and ISCOMs. Vaccine, Kidlinton, v. 21, p. 915-920, 2003.
23. KIKUCHI, H., CARLSSON, A., YACHI, K., HIROTA, S. Possibility of heat sterilization of liposomes. Chem. Pharm. Bull., v. 39, p. 1018-1022, 1991.
24. LABANA, S.; PANDEY, R.; SHARMA, S.; KHULLER, G.K. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes. Int. J. Antimicrob. Agents, London, v. 20, p.301-304, 2002.
25. a ed. Amsterdam: Elsevier Science Publishers B. V., cap.3, p.63-90, 1993.
26. LASIC, D. D. Novel applications of liposomes. Tibtech., v. 16, p. 307-320, 1998.
27. LAVERMAN, P.; BOERMAN, O. C.; OYEN, W. J. G.; DAMS, E. Th. M.; STORM, G.; CORSTENS, F. H. M. Liposomes for scintigraphic detection of infection and inflammation. Adv. Drug Del. Rev., Amsterdam, v. 37, p. 225-235, 1999.
28. LESTINI, B. J.; SAGNELLA, S. M., XU, Z.; SHIVE, M. S.; RICHTER, N. J.; JAYASEHARAN, J.; CASE, A. J.; KOTTKE-MARCHANT, K.; ANDERSON, J. M.; MARCHANT R. E. Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery. J. Controlled Release, Amsterdam, v. 78, p. 235-247, 2002.
29. LU, Y., KAWAKAMI, S., YAMASHITA, F., HASHIDA, M. Development of an antigen-presenting cell-targeted DNA vaccine against melanoma by mannosylated liposomes. Biomaterials, Surrey, v. 28, p. 3255-3262, 2007.
30. LUKYANOV, A. N.; ELBAYOUMI, T. A.; CHAKILAM, A. R.; TORCHILIN, V.P. Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J. Controlled Release, Amsterdam, v. 100, p.135-144, 2004.
31. MAMOT, C.; DRUMMOND, D. C.; HONG, K.; KIRPOTIN, D.B.; PARK, J. W. Liposome-based approaches to overcome anticancer drug resistance. Drug Res. Update, Amsterdam, v. 6, p. 271-279, 2003.
32. MASSING, U.; FUXLUS, S. Liposomal formulations of anticancer drugs: selectivity and effectiveness. Drug Res. Update, Amsterdam, v. 3, p. 171-177, 2000.
33. MAZUMDAR, T.; ANAM, K.; ALI, N. A mixed Th1/Th2 response elicited by a liposomal formulation of leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice. Vaccine, Kidlinton, v. 22, p. 1162-1171, 2004.
34. MELO A. L.; SILVA-BARCELLOS N. M.; DEMICHELI C.; FRÉZARD, F. Enhanced schistosomicidal efficacy of tartar emetic encapsulated in pegylated liposomes. Int. J. Pharm., Amsterdam, v. 255, p.227-230, 2003.
35. MHASHILKARA, A.; CHADA, S.; ROTH, J.; RAMESHB, R. Gene therapy therapeutic approaches and implications. Biotechnol. Adv., New York, v. 19, p. 279-297, 2001.
36. MINATO, S.; IWANAGA, K.; KAKEMI, M.; YAMASHITA, S.; OKU, N. Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccines: effect of lipid dose on systemic and mucosal immunity. J. Controlled Release, Amsterdam, v. 89, p. 189-197, 2003.
37. MOGHIMI, S. M. Opsono-recognition of liposomes by tissue macrophages. Int. J. Pharm., Amsterdam, v. 162, p.11-18, 1998.
38. MORTAZAVI, S.M, MOHAMMADABADI, M.R., KHOSRAVI-DARANI, K., MOZAFARI, M.R. Preparation of liposmal gene therapy vectors by a scalable method without using volatile solvents or detergents. J. Biotechnol., Amsterdam, v. 129, p. 604-613, 2007.
39. MOURÃO, S. C.; COSTA, P. I.; SALGADO, H. R. N.; GREMIÃO, M. P. D. Improved of antischistosomal activity of praziquantel by incorporation into phosphatidylcholine-containing liposomes. Int. J. Pharm., Amsterdam, v. 295, p. 157-162, 2005.
40. MOZAFARI, M.R. Liposomes: an overview of manufacturing techniques. Cell. Mol. Biol. Lett., Washington, v. 10, p. 711-719, 2005.
41. NEEDHAM, D.; McINTOSH, T. J.; LASIC, D. D. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim. Biophys. Acta, Amsterdam, v. 1108, p. 40-48, 1992.
42. NEW, R.R.C. (Ed.). Liposomes: A practical approach, IRL/Oxford University Press, Oxford, 1990. p.432.
43. PUISIEUX, F. COUVREUR, P., DELATTRE, J., DEVISAGUET, J.P. (Eds.). Liposomes, new systems and new trends in their applications. Paris: Éditions de Santé, 1995. p.266.
44. SADZUKA, Y.; SUGIYAMA, I.; TSURUDA, T.; SONOBE, T. Characterization of cytotoxicity of mixed polyethyleneglycol modified liposomes containing doxorubicin. Int. J. Pharm., Amsterdam, v.312, p.83-89, 2006.
45. SAETERN, ANN MARI; SKAR, MERETE; BRAATEN, ASMUND; BRANDL, MARTIN. Camptothecin-catalyzed phospholipid hydrolysis in liposomes. Int. J. Pharm., Amsterdam, v. 288, p.73-80, 2005.
46. SAGRISTÁ, M. L.; MORA, M.; MADARIAGA, M. A. Surface modified liposomes by coating with charged hydrophilic molecules. Cell. Mol. Biol. Lett., Washington, v. 5, p. 19-33, 2000.
47. SANDIP, B. T.; UDUPA, N.; RAO, B. S. S.; DEVI, P. U. Thermosensitive liposomes and localised hyperthermia - an effective bimodality approach for tumour management. Ind. J. Pharmacol., Pondicherry, v. 32, p. 214-220, 2000.
48. SANTANA, M. H. A., OLIVEIRA, M.C., GREMIÃO, P.D. Lipossomas. In: DURAN, N., MATTOSO, L.H.C., DE MORAIS, P.C. (Eds). Nanotecnologia, introdução, preparação e caracterização de nanomateriais e exemplos de aplicação. Artliber, São Paulo, v. 1, p. 167-173, 2006.
49. SAPRA, P.; ALLEN, T. M. Ligand-targeted liposomal anticancer drugs. Prog. Lipid Res., Oxford, v. 42, p. 439-462, 2003.
50. SCHETTINI, D. A.; RIBEIRO, R. R.; DEMICHELI, C.; ROCHA, O. G. F.; MELO, M. N.; MICHALICK, M. S. M.; FRÉZARD, F. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. Int. J. Pharm., Amsterdam, v. 315, n. 1-2, p.140-147, 2006.
51. SCHNEIDER, T., SACHSE, A., RObLING, G., BRANDL, M. Large scale production of liposomesof defined size bya new continuous high pressure extrusion device. Drug Dev. Ind. Pharm., Bethesda, v. 20, p. 2787-2807, 1994.
52. SENGUPTA, S.; TYAGI, P.; VELPANDIAN, T.; GUPTA, Y. K.; GUPTA, S. K. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol. Res., London, v. 42, n. 5, p. 459-464, 2000.
53. SERIKAWA, T., KIKUCHI, A., SUGAYA, S., SUZUKI, N., KIKUCHI, H., TANAKA, K. In vitro e in vivo evaluation of novel cationic liposomes utilized for cancer gene therapy. J. Controlled Release, Amsterdam, v. 113, p. 255-260, 2006.
54. SHARMA, A.; SHARMA, U. S. Liposome in drug delivery: progress and limitations. Int. J. Pharm., Amsterdam, v. 154, p.123-140, 1997.
55. SIHORKAR, V.; VYAS, S. P. Potential of polysaccharide anchored liposomes in drug delivery, targeting and immunization. J. Pharm. Sci., Hoboken, v. 4, n. 2, p. 138-158, 2001.
56. SINGH, M.; O'HAGAN, D. T. Recent advances in veterinary vaccine adjuvants. Int. J. Parasitol., Oxford, v. 33, p. 469-478, 2003.
57. SUZUKI, S., KAWAKAMI, S., CHANSRI, N., YAMASHITA, F., HASHIDA, M. Inhibition of pulmonary metastasis in mice by all-trans retinoic acid incorporated in cationic liposomes. J. Controlled Release, Amsterdam, v. 116, p. 58-63, 2006.
58. TORCHILIN, V.P. Drug targeting. Eur. J. Pharm. Sci., Amsterdam, p.s81-s91, 2000.
59. TORCHILIN, V.P. Recent advances with liposomes as pharmaceutical carrier. Nature Rev. Drug Disc., London, v. 4, p. 145-160, 2005.
60. VEMURI, S.; RHODES, C. T. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm. Acta Helvetica, Berne, v. 70, p.95-111, 1995.
61. VONARBOURG, A.; PASSIRANI, C.; SAULNIER, P.; BENOIT, J. Parameters influencing the stealthiness of colloidal drug delivery systems. Biomaterials, Surrey, v. 27, p.4356-4373, 2006.
62. WAGNER, A., VORAUER-UHL, K., KATINGER, H. Liposomes produced in a pilot scale: production, purification and efficiency aspects. Eur. J. Pharm. Biopharm., Amsterdam, v. 54, p. 213-219, 2002.
63. WU, J., LEE, A., LU, Y., LEE, R.J. Vascular targeting of doxorubicin using cationic liposomes. Int. J. Pharm., Amsterdam, 2007, doi: 10.1016/j.ijpharm.2007.01.003.
64. YAROSH, D. B. Liposomes in investigative dermatology. Photodermatol. Photoimmunol. Photomed., Denmark, v. 17, p. 203-212, 2001.
65. ZHANG, N.; PING, Q. N.; HUANG, G. H.; XU, W. F. Investigation of lectin-modified insulin liposomes as carriers for oral administration. Int. J. Pharm., Amsterdam, v. 294, p.247-259, 2005.
66. ZHAO, X. B.; LEE, R. J. Tumor-selective targeted delivery of genes and antisense oligodeoxyribonucleotides via the folate receptor. Adv. Drug Del. Rev., Amsterdam, v. 56, p. 1193-1204, 2004.